Filoviruses and arenaviruses are two major families of lethal hemorrhagic fever viruses for which no vaccines or treatments are currently available. Previous work by several investigators involved in this proposal has unequivocally demonstrated the feasibility of protecting non-human primates against viral challenge with immunotherapy. This highly translational proposal will identify the most effective monoclonal antibodies and from them, create broad-spectrum antibody cocktails for pre- or post-exposure use. To achieve this goal, we will leverage the consortium's large collection of anti-filovirus and anti-arenavirus antibodies, as well as new antibodies to be derived from ongoing and proposed discovery efforts. However, it will not be feasible to test each of our hundreds of candidate antibodies and thousands of potential antibody combinations in animals without some initial in vitro downselection. To generate a manageable set of candidate antibodies and cocktails, Core C (working together the three project teams and the Gore D team) will categorize antibodies into structural and functional groups, perform rules-based triage of antibody candidates, and design antibody cocktails based on antiviral activity and functional diversity. Finally and importantly. Core C will prioritize candidate cocktails based on their susceptibility to escape mutations, and will, together with Core D, identify antibodies most resistant to escape, as well as replacement antibodies that will """"""""mop up"""""""" escaping virions. In addition to selection of the most effective single antibodies and cocktails of antibodies to forward for patient use, this Gore will provide essential information that addresses major, basic knowledge gaps in the field. Our comprehensive analysis will illustrate which epitopes lead to the most effective protection, which in vitro assays are the best predictors of in vivo efficacy, and which epitopes lead to broad-spectrum reactivity and protection.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
King, Liam B; West, Brandyn R; Schendel, Sharon L et al. (2018) The structural basis for filovirus neutralization by monoclonal antibodies. Curr Opin Immunol 53:196-202
Amanat, Fatima; Duehr, James; Oestereich, Lisa et al. (2018) Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. mSphere 3:
Flyak, Andrew I; Kuzmina, Natalia; Murin, Charles D et al. (2018) Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol 3:670-677
Murin, Charles D; Bruhn, Jessica F; Bornholdt, Zachary A et al. (2018) Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop. Cell Rep 24:2723-2732.e4
King, Liam B; Fusco, Marnie L; Flyak, Andrew I et al. (2018) The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. Cell Host Microbe 23:101-109.e4
Saphire, Erica Ollmann; Schendel, Sharon L; Fusco, Marnie L et al. (2018) Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell 174:938-952.e13
Siragam, Vinayakumar; Wong, Gary; Qiu, Xiang-Guo (2018) Animal models for filovirus infections. Zool Res 39:15-24
West, Brandyn R; Moyer, Crystal L; King, Liam B et al. (2018) Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. MBio 9:
Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573
Yang, Shu; Xu, Miao; Lee, Emily M et al. (2018) Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov 4:31

Showing the most recent 10 out of 62 publications